Recordati's ISTURISA® Presentation at AACE
Recordati Rare Diseases is gearing up to present vital information about ISTURISA® (osilodrostat) at the American Association of Clinical Endocrinology (AACE) Annual Meeting. This year’s event showcases the expanded indication for ISTURISA®, particularly for adult patients grappling with endogenous hypercortisolemia due to Cushing's syndrome, for whom surgical options are unviable or non-curative.
Understanding ISTURISA®
ISTURISA® serves as an effective cortisol synthesis inhibitor, working by blocking the enzyme 11beta-hydroxylase. This mechanism helps normalize cortisol levels in patients suffering from Cushing's syndrome, which is a rare yet severe endocrine disorder that significantly affects lives. The broader indication for ISTURISA® is backed by a comprehensive clinical development program that includes extensive data supporting its efficacy and safety.
What to Expect at AACE 2025
During the AACE Annual Meeting, attendees can discover further insights into the indications of ISTURISA®. The company will host informational booths, providing commercial and medical expertise regarding the expanded use of the drug. A fascinating highlight will be the presentation of the LINC 6 study poster, which showcases robust data on ISTURISA®’s long-term safety and effectiveness. This will underscore the commitment of Recordati Rare Diseases to enhancing treatment solutions for this complex illness.
Expert Commentary
Dr. Mario Maldonado, the Head of Development and Global Endocrinology at Recordati Rare Diseases, expressed enthusiasm about the expanded label for ISTURISA®. He noted, "We are thrilled to share our new findings about the label expansion at AACE 2025. The LINC 6 study presents crucial insights into the safety and efficacy of ISTURISA® for managing Cushing's syndrome, showcasing our commitment to advancing treatment for those challenged by this condition." The thorough analysis available from the LINC 6 study will further empower healthcare providers to manage patient health effectively.
Highlighted Presentations at AACE 2025
During the AACE Annual Meeting, Recordati will conduct various informative sessions. Here are key highlights:
- Visit Booth #109 for in-depth discussions on the expanded ISTURISA® indication and implications for treating Cushing's syndrome.
- LINC 6 Poster Presentation (Session #792): This session features an analysis of the long-term safety and efficacy of osilodrostat in patients enrolled in the multinational LINC 6 study. This will take place on May 15.
- Product Theater Session 1: “Is Cortisol the Culprit?”—an interactive panel discussion on recognizing signs and symptoms of endogenous hypercortisolemia will occur on May 16.
- Product Theater Session 2: “Breaking Barriers in Acromegaly”—focusing on personalized treatment approaches on the same day.
About ISTURISA®
ISTURISA® plays a pivotal role in treating endogenous hypercortisolemia in adult patients characterized by raised cortisol levels due to Cushing's syndrome. This treatment pathway serves those unable to undergo surgery or who haven't achieved a cure post-surgery. It is essential to acknowledge the impacts of untreated hypercortisolemia, which can lead to serious complications, including diabetes, cardiovascular issues, and more. ISTURISA® was classically developed with a clear focus on patient needs, evidenced by clinical results from over 350 participants in various studies.
Implications of Untreated Cushing's Syndrome
Cushing's syndrome can pose severe health risks characterized by excessive cortisol levels. Patients may experience debilitating symptoms such as weight gain, high blood sugar, hypertension, and psychological distress. If unmanaged, these symptoms can lead to grave outcomes, including heightened diabetes risk and cardiovascular complications. Therefore, early diagnosis and effective management of hypercortisolemia are crucial.
Future Directions for Recordati
Recordati is committed to innovation in patient care. With ISTURISA® already approved for the treatment of Cushing's syndrome in numerous countries, including its recent approval in the European Union and China, the company is eager to continue expanding treatment efficacy globally. The underlying aim is to ensure that individuals facing this complex disorder have access to reliable and safe medical solutions.
Frequently Asked Questions
What is ISTURISA® used for?
ISTURISA® is utilized for treating adults with endogenous hypercortisolemia resulting from Cushing's syndrome.
Who can benefit from ISTURISA®?
This medication is particularly beneficial for individuals who cannot undergo surgery or whose surgery has not cured their Cushing's syndrome.
How does ISTURISA® work?
It acts as a cortisol synthesis inhibitor by blocking the enzyme 11beta-hydroxylase, normalizing elevated cortisol levels.
What should be considered before starting ISTURISA®?
Patients should inform their healthcare providers of any medical conditions, particularly heart issues, liver problems, or pregnancy status.
Are there any common side effects of ISTURISA®?
Common side effects include low cortisol levels, fatigue, nausea, headaches, and fluid retention.
